Cargando…

Tumour budding and tumour–stroma ratio in hepatocellular carcinoma

BACKGROUND: Tumour budding and low tumour–stroma ratio (TSR) are associated with poor prognosis in some cancers, but their value in Western hepatocellular carcinoma is unclear. The prognostic value of tumour budding and TSR in hepatocellular carcinoma was examined. METHODS: Some 259 hepatocellular c...

Descripción completa

Detalles Bibliográficos
Autores principales: Kairaluoma, Valtteri, Kemi, Niko, Pohjanen, Vesa-Matti, Saarnio, Juha, Helminen, Olli
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7341881/
https://www.ncbi.nlm.nih.gov/pubmed/32362654
http://dx.doi.org/10.1038/s41416-020-0847-1
_version_ 1783555325273571328
author Kairaluoma, Valtteri
Kemi, Niko
Pohjanen, Vesa-Matti
Saarnio, Juha
Helminen, Olli
author_facet Kairaluoma, Valtteri
Kemi, Niko
Pohjanen, Vesa-Matti
Saarnio, Juha
Helminen, Olli
author_sort Kairaluoma, Valtteri
collection PubMed
description BACKGROUND: Tumour budding and low tumour–stroma ratio (TSR) are associated with poor prognosis in some cancers, but their value in Western hepatocellular carcinoma is unclear. The prognostic value of tumour budding and TSR in hepatocellular carcinoma was examined. METHODS: Some 259 hepatocellular carcinoma patients treated in Oulu University Hospital 1983–2018 were included in this retrospective cohort study. Tumour budding and TSR were analysed from the haematoxylin- and eosin-stained original diagnostic slides, by dividing patients into bud-negative (0 bud) or bud-positive (≥1 bud) groups, and into high TSR (<50%) and low TSR (≥50%) groups. Surgically treated patients (n = 47) and other treatments (n = 212) were analysed separately. Primary outcomes were overall, and disease-specific 5-year mortality was adjusted for confounding factors. RESULTS: Surgically treated patients with positive tumour budding had increased 5-year overall (adjusted HR 3.87, 95% CI 1.10–13.61) and disease-specific (adjusted HR 6.17, 95% CI 1.19–31.90) mortality compared with bud-negative patients. In surgically treated patients, TSR had no effect on 5-year overall (adjusted HR 2.03, 95% CI 0.57–7.21) or disease-specific (adjusted HR 3.23, 95% CI 0.78–13.37) mortality. No difference in survival related to tumour budding and TSR in non-surgically treated patients was observed. CONCLUSIONS: Tumour budding is a prognostic factor in surgically treated hepatocellular carcinoma.
format Online
Article
Text
id pubmed-7341881
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-73418812021-05-04 Tumour budding and tumour–stroma ratio in hepatocellular carcinoma Kairaluoma, Valtteri Kemi, Niko Pohjanen, Vesa-Matti Saarnio, Juha Helminen, Olli Br J Cancer Article BACKGROUND: Tumour budding and low tumour–stroma ratio (TSR) are associated with poor prognosis in some cancers, but their value in Western hepatocellular carcinoma is unclear. The prognostic value of tumour budding and TSR in hepatocellular carcinoma was examined. METHODS: Some 259 hepatocellular carcinoma patients treated in Oulu University Hospital 1983–2018 were included in this retrospective cohort study. Tumour budding and TSR were analysed from the haematoxylin- and eosin-stained original diagnostic slides, by dividing patients into bud-negative (0 bud) or bud-positive (≥1 bud) groups, and into high TSR (<50%) and low TSR (≥50%) groups. Surgically treated patients (n = 47) and other treatments (n = 212) were analysed separately. Primary outcomes were overall, and disease-specific 5-year mortality was adjusted for confounding factors. RESULTS: Surgically treated patients with positive tumour budding had increased 5-year overall (adjusted HR 3.87, 95% CI 1.10–13.61) and disease-specific (adjusted HR 6.17, 95% CI 1.19–31.90) mortality compared with bud-negative patients. In surgically treated patients, TSR had no effect on 5-year overall (adjusted HR 2.03, 95% CI 0.57–7.21) or disease-specific (adjusted HR 3.23, 95% CI 0.78–13.37) mortality. No difference in survival related to tumour budding and TSR in non-surgically treated patients was observed. CONCLUSIONS: Tumour budding is a prognostic factor in surgically treated hepatocellular carcinoma. Nature Publishing Group UK 2020-05-04 2020-07-07 /pmc/articles/PMC7341881/ /pubmed/32362654 http://dx.doi.org/10.1038/s41416-020-0847-1 Text en © The Author(s), under exclusive licence to Cancer Research UK 2020 https://creativecommons.org/licenses/by/4.0/Note This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0).
spellingShingle Article
Kairaluoma, Valtteri
Kemi, Niko
Pohjanen, Vesa-Matti
Saarnio, Juha
Helminen, Olli
Tumour budding and tumour–stroma ratio in hepatocellular carcinoma
title Tumour budding and tumour–stroma ratio in hepatocellular carcinoma
title_full Tumour budding and tumour–stroma ratio in hepatocellular carcinoma
title_fullStr Tumour budding and tumour–stroma ratio in hepatocellular carcinoma
title_full_unstemmed Tumour budding and tumour–stroma ratio in hepatocellular carcinoma
title_short Tumour budding and tumour–stroma ratio in hepatocellular carcinoma
title_sort tumour budding and tumour–stroma ratio in hepatocellular carcinoma
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7341881/
https://www.ncbi.nlm.nih.gov/pubmed/32362654
http://dx.doi.org/10.1038/s41416-020-0847-1
work_keys_str_mv AT kairaluomavaltteri tumourbuddingandtumourstromaratioinhepatocellularcarcinoma
AT keminiko tumourbuddingandtumourstromaratioinhepatocellularcarcinoma
AT pohjanenvesamatti tumourbuddingandtumourstromaratioinhepatocellularcarcinoma
AT saarniojuha tumourbuddingandtumourstromaratioinhepatocellularcarcinoma
AT helminenolli tumourbuddingandtumourstromaratioinhepatocellularcarcinoma